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1. Introduction {#sec005}
===============

The steady growth in the number of surgical procedures is a consequence of increased life expectancy and better surgical techniques \[[@pone.0237740.ref001]\]. Gastrointestinal surgeries are among the most performed surgical procedures, especially those related to the resection of tumors \[[@pone.0237740.ref002]\]. It is up to the medical team, together with the patient, to analyse the risks of each surgery and decide which is the best therapeutic option \[[@pone.0237740.ref001]\]. In this context, tools have been developed to assist in this decision, such as the Charlson Comorbidity Index, so the factors that contribute to the success of the procedure can be evaluated \[[@pone.0237740.ref003]\].

These factors can be divided into those intrinsic to the disease process, such as the pathophysiological characteristics of a tumor and its staging, and those related to the patient. In relation to the latter, some of the factors that are very prevalent in the population, such as sarcopenia, have not yet been included in the analysis tools due to the scarcity of studies that accurately determine its impact on surgical procedures.

Sarcopenia is defined as the loss of muscle mass combined with loss of muscle strength, with or without loss of muscle performance \[[@pone.0237740.ref004],[@pone.0237740.ref005]\]. Evidence indicates that it starts in the fifth decade of life and has a linear progression, being characterized as primary \[[@pone.0237740.ref006],[@pone.0237740.ref007]\]. There is also the secondary form that results from a pathological process, as in the case of chronic-degenerative diseases, malnutrition, and chronic inflammation \[[@pone.0237740.ref008]\]. In addition, some studies emphasize the importance of vitamin D deficiency \[[@pone.0237740.ref009]\] and insulin resistance \[[@pone.0237740.ref010]\] in the pathogenesis of the disease. Considering that muscle mass represents approximately 60% of the body mass and is metabolically active, it is expected that sarcopenia affects homeostasis substantially \[[@pone.0237740.ref011]\]. From a histological point of view, there is a reduction in the size and number of muscle cells, especially type 2, and infiltration of fibrosis and fat \[[@pone.0237740.ref012]\].

All of these changes have a great impact on the lives of individuals, from decreased ability to perform daily activities \[[@pone.0237740.ref013]\], falls, increased prevalence of frailty syndrome \[[@pone.0237740.ref014]--[@pone.0237740.ref016]\] and, especially, in the state of acute and chronic diseases, increased mortality and comorbidity \[[@pone.0237740.ref017]\].

Given the importance of sarcopenia as one of the determining factors to the success of surgery, it is essential that there are precise ways of diagnosing it. Many articles use only muscle mass to diagnose sarcopenia, mainly due to the fact it is easy to obtain such data from imaging tests that would already be performed on patients regardless. Therefore, one of the most common methods used is the cross-sectional area of skeletal muscles on abdominal CT at the level of the third lumbar vertebra (L3) \[[@pone.0237740.ref018]--[@pone.0237740.ref022]\]. However, according to The European Working Group on Sarcopenia in Older People (EWGSOP), this data alone is not enough: in addition to the loss of muscle mass, it is necessary to have an assessment of strength and / or physical performance for it to be verified sarcopenia\[[@pone.0237740.ref004]\]. Regarding the measurement of muscle strength, the most used and validated form is the hand grip exam---non-dominant hand grip strength \[[@pone.0237740.ref023],[@pone.0237740.ref024]\].

This review aims to analyse articles that have assessed the presence of sarcopenia in adult patients, according to the recommended criteria, and to relate this factor to the outcome of gastrointestinal surgeries.

2. Materials and methods {#sec006}
========================

This systematic review and meta-analysis was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@pone.0237740.ref025]\].

The elaboration of the scientific question was based on the PICO strategy \[[@pone.0237740.ref026]\] considering:

1.  P---Patient/Problem--adult patients undergoing gastrointestinal surgery;

2.  I--Intervention/ Prognosis Factor---presence or absence of a diagnosis of sarcopenia, according to internationally recognized methods;

3.  C--Control/ Comparison---there is no standard intervention to be considered in this study;

4.  O--Outcome---influence of sarcopenia on early and late postoperative results.

2.1 Eligibility criteria {#sec007}
------------------------

The following criteria were adopted for the inclusion of studies in this review:

1.  They must report results of surgical interventions of a gastrointestinal nature (e.g. hernia, colectomy, GI oncology) regarding the presence of the diagnosis of sarcopenia, in patients aged 18 years or older.

2.  Sarcopenia must be related to age (primary) or underlying disease (secondary).

3.  The description of the post-surgical results must have at least one of the following data: postoperative complications, infectious complications, complications of a clinical nature, and mortality data. They can be early, late or both.

2.2 Exclusion criteria {#sec008}
----------------------

The exclusion criteria were:

1.  Diagnosis of sarcopenia based on purely laboratory or imaging criteria (for example, tomography only).

2.  Sarcopenia secondary to intervention (e.g. post-transplant, post-chemotherapy).

3.  Studies involving surgeries of a different nature than gastrointestinal

4.  Letters to editors, incomplete unpublished articles and research protocols.

2.3 Types of studies {#sec009}
--------------------

Retrospective and prospective cohort studies that compared gastrointestinal surgery outcomes in sarcopenic and non-sarcopenic patients were included.

2.4 Data search strategy and literature review {#sec010}
----------------------------------------------

The study was registered in the PROSPERO database under number CRD42019132221. Two independent reviewers performed a systematic search of the PubMed and EMBASE databases; only articles in the English language were searched. The period sought database inception to the 3rd of April 2020. The systematic review followed the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) \[[@pone.0237740.ref025]\].

Using the PubMed search tool, we selected the MeSH terms of the most relevant publications to conduct a new search in order to obtain more articles that could potentially be included in this review.

The keywords used for were: sarcopenia, muscle wasting, gastrointestinal surgery, complications, outcomes, and mortality.

PUBMED: (\"Sarcopenia\"\[Mesh\] OR \"Muscular Atrophy\"\[Mesh\] OR \"Frailty\"\[Mesh\]) AND (\"Digestive System Surgical Procedures\"\[Mesh\] OR "gastrointestinal surgery") AND (\"Patient Outcome Assessment\"\[Mesh\] OR \"Postoperative Complications\"\[Mesh\] OR \"Mortality\"\[Mesh\]): → 167.

EMBASE: (\'sarcopenia\'/exp OR \'sarcopenia\' OR \'muscular atrophy\'/exp OR \'muscular atrophy\' OR \'frailty\'/exp OR \'frailty') AND (\'digestive system surgical procedures\'/exp OR \'digestive system surgical procedures\' OR \'gastrointestinal surgery\'/exp OR \'gastrointestinal surgery\') AND (\'patient outcome assessment\'/exp OR \'patient outcome assessment\' OR \'postoperative complications\'/exp OR \'postoperative complications\' OR \'mortality\'/exp OR \'mortality') → 1245.

2.5 Selection of studies and data extraction {#sec011}
--------------------------------------------

Based on the criteria mentioned above, the headlines and abstracts of the studies were initially screened by two independent reviewers. Relevant articles were assessed for methodology, especially for the method of diagnosing sarcopenia. After this second screening, the remaining articles were read in full to define their inclusion in the review. Disagreeing cases were resolved with a third reviewer (AM).

The main data for each article included in the review were extracted by a reviewer (LP). The following were tabled: article headline, authors, year of publication, country of origin, basic characteristics of the study populations, study design, study objectives, sample size, inclusion and exclusion criteria, gender relationship, prevalence of sarcopenia, method used to diagnose sarcopenia, type of surgery, primary and secondary outcomes regarding the presence or absence of sarcopenia. The data were checked by another reviewer (CGB).

2.6 Data quality analysis {#sec012}
-------------------------

The studies included in the review were assessed for the quality of the data presented using the MINORS tool (Methodological Index for Non-Randomized Studies) \[[@pone.0237740.ref027]\]. The instrument consists of eight items for non-comparative studies, plus four other items for comparative studies. The LP and CGB reviewers performed the methodological quality analysis of the studies as described, and inconclusive cases were assessed by a third reviewer (AM).

2.7 Statistical analysis {#sec013}
------------------------

Heterogeneity measures were used to evaluate the studies, Higgins I2 measure, which indicates the variation in the association measure attributable to heterogeneity. The Cochran test under the null hypothesis that there is no heterogeneity was calculated. Fixed effects regression model was used for the data analysis. The overall effect was assessed under the null hypothesis that the odds ratio (OR) = 1 (there is no effect between the exposure levels).

1.  The graphs of forest plot and funnel plot (to assess publication bias) were performed.

2.  The subgroup analysis was performed based on the type of surgery in each study.

3.  The analyses were performed using the statistical software RStudio Team (2015). RStudio: Integrated Development for R. RStudio, Inc., Boston, MA

3. Results {#sec014}
==========

3.1 Selected studies {#sec015}
--------------------

The search strategy resulted in 1323 articles. After removing duplicate articles, 1177 remained. These underwent initial screening, focusing on headlines and abstracts. After this initial screening, 108 articles remained for evaluation of the full text. Of these, 11 articles had the necessary characteristics for inclusion \[[@pone.0237740.ref028]--[@pone.0237740.ref038]\]. ([Fig 1](#pone.0237740.g001){ref-type="fig"}).

![Data search flow.](pone.0237740.g001){#pone.0237740.g001}

3.2 Population characteristics {#sec016}
------------------------------

Of the selected studies, eight involved patients with gastric cancer \[[@pone.0237740.ref029]--[@pone.0237740.ref034],[@pone.0237740.ref036],[@pone.0237740.ref037]\], two with colorectal cancer \[[@pone.0237740.ref028],[@pone.0237740.ref038]\], and one with esophageal cancer \[[@pone.0237740.ref035]\]. The total number of subjects evaluated was 4265, between sarcopenic and non-sarcopenic. All studies associated imaging with functional testing for the diagnosis of sarcopenia, and all originated in two countries: Japan \[[@pone.0237740.ref031],[@pone.0237740.ref035],[@pone.0237740.ref037]\] and China \[[@pone.0237740.ref028]--[@pone.0237740.ref030],[@pone.0237740.ref032]--[@pone.0237740.ref034],[@pone.0237740.ref036],[@pone.0237740.ref038]\]. [Table 1](#pone.0237740.t001){ref-type="table"} summarizes the population characteristics of each study.

10.1371/journal.pone.0237740.t001

###### Population characteristics of the 11 selected studies.

![](pone.0237740.t001){#pone.0237740.t001g}

  Author, Year    Study design    Type of surgery     N total   Sarcopenia prevalence   Age             Sex ratio: M/F                         Data collection period   Country                                                                              
  --------------- --------------- ------------------- --------- ----------------------- --------------- -------------------------------------- ------------------------ -------------------------------------- ------ ------ ------------------------------- -------
  Huang 2015      Prospective     Colorectal Cancer   142       12.00%                  74.59 (6.65)    [•](#t001fn002){ref-type="table-fn"}   60.32 (12.24)            [•](#t001fn002){ref-type="table-fn"}   1.83   1.60   August 2014 and February 2015   China
  Fukuda 2016     Retrospective   Gastric Cancer      99        21.20%                  78 (67--85)     [†](#t001fn001){ref-type="table-fn"}   75 (66--91)              [†](#t001fn001){ref-type="table-fn"}   9.50   1.52   July 2012 and January 2015      Japan
  Wang 2016       Prospective     Gastric Cancer      255       12.50%                  74.66 (6.80)    [•](#t001fn002){ref-type="table-fn"}   63.77 (10.66)            [•](#t001fn002){ref-type="table-fn"}   4.33   2.78   August 2014 to March 2015       China
  Huang 2017      Prospective     Gastric Cancer      470       16.80%                  63 (4)          [†](#t001fn001){ref-type="table-fn"}   74 (10)                  [†](#t001fn001){ref-type="table-fn"}   2.95   3.32   August 2014 to December 2015    China
  Lou 2017        Prospective     Gastric Cancer      206       6.80%                   74.78 (5.08)    [•](#t001fn002){ref-type="table-fn"}   63.27 (9.93)             [•](#t001fn002){ref-type="table-fn"}   1.80   3.80   August 2014 to December 2015    China
  Zhou 2017       Prospective     Gastric Cancer      240       28.80%                  76 (6.5)        [•](#t001fn002){ref-type="table-fn"}   71 (7)                   [•](#t001fn002){ref-type="table-fn"}   3.06   4.18   August 2014 to December 2015    China
  Kawamura 2018   Retrospective   Gastric Cancer      951       11.70%                  76 (65--90)     [†](#t001fn001){ref-type="table-fn"}   72.5 (65--87)            [†](#t001fn001){ref-type="table-fn"}   1.64   2.37   July 2003 and June 2011         Japan
  Makiura 2018    Prospective     Esophageal Cancer   113       31.60%                  69 (65--75)     [†](#t001fn001){ref-type="table-fn"}   64 (61--70)              [†](#t001fn001){ref-type="table-fn"}   3.86   7.37   June 2011 to November 2014      Japan
  Chen 2018       Prospective     Colorectal Cancer   376       24.50%                  70.73 (12.61)   [•](#t001fn002){ref-type="table-fn"}   59.20 (13.0)             [•](#t001fn002){ref-type="table-fn"}   2.00   2.04   July 2014 to February 2017      China
  Ma 2019         Prospective     Gastric Cancer      545       7.30%                   70.63(11.13)    [•](#t001fn002){ref-type="table-fn"}   61.93(10.20)             [•](#t001fn002){ref-type="table-fn"}   1.67   3.50   August 2014 to December 2017    China
  Zhuang 2019     Prospective     Gastric Cancer      883       35.90%                  73.54 (7.50)    [•](#t001fn002){ref-type="table-fn"}   \-                                                              2.40   \-     August 2014 to February 2018    China

† mean (sd).

^•^ median (IQR).

3.3 Quality assessment using the MINORS score {#sec017}
---------------------------------------------

[Table 2](#pone.0237740.t002){ref-type="table"} describes the score received by each study in the quality assessment\[[@pone.0237740.ref028]--[@pone.0237740.ref038]\]. Through the MINORS scale, up to 24 points can be awarded for comparative studies; the score of the studies included in this review ranged from 16 to 22. The main factors that led to the loss of points were a very short follow-up period regarding the objectives of the study, and the retrospective design. None of the articles performed a prospective calculation of the sample size.

10.1371/journal.pone.0237740.t002

###### 

ORS score for quality assessment (A). Criteria used for the assessment (B).

![](pone.0237740.t002){#pone.0237740.t002g}

  A                                                                              B
  --------------- --- --- --- --- --- --- --- --- --- ---- ---- ---- ----------- ----------------------------------------------------------
  Study           1   2   3   4   5   6   7   8   9   10   11   12   **TOTAL**   Criteria:
  Huang 2015      2   2   2   2   2   1   2   0   2   2    1    2    **20**      1---Clearly stated aim
  Fukuda 2016     2   2   0   2   0   1   2   0   2   2    2    2    **17**      2---Inclusion of consecutive patients
  Wang 2016       2   2   2   2   2   2   2   0   2   2    2    2    **22**      3---Prospective collection of data
  Huang 2017      1   2   2   2   2   1   2   0   2   2    2    2    **20**      4---Endpoints appropriate to the aim of the study
  Lou 2017        2   2   2   2   2   1   2   0   2   2    1    2    **20**      5---Unbiased assessment of the study endpoint
  Zhou 2017       2   2   2   2   2   2   2   0   2   2    2    2    **22**      6---Follow-up period appropriate to the aim of the study
  Kawamura 2018   1   2   0   2   0   2   2   0   2   2    2    2    **17**      7---Loss to follow up less than 5%
  Makiura 2018    2   2   2   2   0   2   0   0   2   2    2    2    **18**      8---Prospective calculation of the study size
  Chen 2018       2   2   2   2   2   2   2   0   2   2    2    2    **22**      9---An adequate control group
  Ma 2019         2   2   2   2   2   2   2   0   2   2    1    2    **21**      10---Contemporary groups
  Zhuang 2019     2   2   2   2   0   2   2   0   2   2    2    2    **20**      11---Baseline equivalence of groups
                                                                                 12---Adequate statistical analyses

3.4 Criteria for the diagnosis of sarcopenia {#sec018}
--------------------------------------------

The most used classifications for the diagnosis of sarcopenia that do not use only imaging criteria are AWGS \[[@pone.0237740.ref039]\], EWGSOP2 \[[@pone.0237740.ref040]\], IWGS \[[@pone.0237740.ref041]\] e FNIH\[[@pone.0237740.ref042]\] ([Fig 2](#pone.0237740.g002){ref-type="fig"}). However, studies show that the criteria EWGSOP2 and AWGS are the ones that best rate sarcopenia \[[@pone.0237740.ref043]\]. Thus, these were the criteria for the inclusion of articles. The diagnosis was made after confirmation of reduced muscle mass combined with loss of strength and / or muscle performance. The method for assessing muscle strength in all studies was the hand-grip; muscle performance assessment was performed in all studies, except one \[[@pone.0237740.ref037]\]. The evaluation was made through the usual walking speed, with distances ranging between 4m and 6m. The most widely used method for assessing muscle mass was tomography, with assessment of the skeletal muscle index at the level of the third lumbar vertebra and specific cutoff points for each sex \[[@pone.0237740.ref028]--[@pone.0237740.ref030],[@pone.0237740.ref032]--[@pone.0237740.ref034],[@pone.0237740.ref036],[@pone.0237740.ref038]\]. Two studies used bioimpedance to calculate the appendicular skeletal muscle index \[[@pone.0237740.ref031],[@pone.0237740.ref035]\]; one study used anthropometric measurements to calculate the muscular circumference of the arm \[[@pone.0237740.ref037]\].

With these criteria, the prevalence of sarcopenia between studies ranged from 6.8% to 35.9%. The data related to the sarcopenia diagnostic method are summarized in [Table 3](#pone.0237740.t003){ref-type="table"}.

![Most used classifications for sarcopenia.\
EWGSOP2 and AWGS form the criteria selected for inclusion in this systematic review and meta-analysis.](pone.0237740.g002){#pone.0237740.g002}

10.1371/journal.pone.0237740.t003

###### Methods used for the diagnosis of sarcopenia.

![](pone.0237740.t003){#pone.0237740.t003g}

  Author, Year    Muscle Mass Evaluation                                           Cut-off points                                                                                           Strength Evaluation   Cut-off points               Performance evaluation   Cut-off points   Sarcopenia Diagnosis Criteria
  --------------- ---------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------- ---------------------------- ------------------------ ---------------- -------------------------------
  Huang 2015      Sex-specific L3 skeletal muscle index (CT images)                SMI \< 36 cm2/m2 for men, \< 29 cm2/m2 for women                                                         Hand-grip             \< 26kg men, \< 18kg women   6m usual gait speed      \<0.8m/s         EWGSOP, AWGS
  Fukuda 2016     Bioimpedance analysis---skeletal muscle mass index               SMI \< 8.87 kg/m2 for men, \< 6.42 kg/m2 for women                                                       Hand-grip             \< 30kg men, \< 20kg women   4m usual gait speed      \<0.8m/s         EWGSOP
  Wang 2016       Sex-specific L3 skeletal muscle index (CT images)                SMI \< 36 cm2/m2 for men, \< 29 cm2/m2 for women                                                         Hand-grip             \< 26kg men, \< 18kg women   6m usual gait speed      \<0.8m/s         EWGSOP, AWGS
  Huang 2017      Sex-specific L3 skeletal muscle index (CT images)                SMI \< 40.8 cm2/m2 for men, 34.9 cm2/m2 for women                                                        Hand-grip             \< 26kg men, \< 18kg women   6m usual gait speed      \<0.8m/s         EWGSOP
  Lou 2017        Sex-specific L3 skeletal muscle index (CT images)                SMI \< 40.8 cm2/m2 for men, 34.9 cm2/m2 for women                                                        Hand-grip             \< 26kg men, \< 18kg women   6m usual gait speed      \<0.8m/s         AWGS
  Zhou 2017       Sex-specific L3 skeletal muscle index (CT images)                SMI \< 40.8 cm2/m2 for men, 34.9 cm2/m2 for women                                                        Hand-grip             \< 26kg men, \< 18kg women   6m usual gait speed      \<0.8m/s         EWGSOP, AWGS
  Kawamura 2018   Anthropometry---Arm Muscle Area                                  Muscle mass \< 20th sex-specific percentile                                                              Hand-grip             \< 26kg men, \< 18kg women   Not obtained             Not obtained     AWGS
  Makiura 2018    Multi- frequency bioelectrical impedance with eight electrodes   Appendicular skeletal muscle mass divided by squared height. \< 7 kg/m2 for men, \< 5.7kg/m2 for women   Hand-grip             \< 26kg men, \< 18kg women   4m usual gait speed      \<0.8m/s         AWGS
  Chen 2018       Sex-specific L3 skeletal muscle index (CT images)                SMI \< 40.8 cm2/m2 for men, \< 34.9 cm2/m2 for women                                                     Hand-grip             \< 26kg men, \< 18kg women   6m usual gait speed      \<0.8m/s         AWGS
  Ma 2019         Sex-specific L3 skeletal muscle index (CT images)                SMI \< 40.8 cm2/m2 for men, \< 34.9 cm2/m2 for women                                                     Hand-grip             \< 26kg men, \< 18kg women   6m usual gait speed      \<0.8m/s         EWGSOP
  Zhuang 2019     Sex-specific L3 skeletal muscle index (CT images)                SMI \< 40.8 cm2/m2 for men, \< 34.9 cm2/m2 for women                                                     Hand-grip             \< 26kg men, \< 18kg women   6m usual gait speed      \<0.8m/s         EWGSOP

3.5 Outcomes {#sec019}
------------

### 3.5.1 Sarcopenia and postoperative complications {#sec020}

In all 11 studies \[[@pone.0237740.ref028]--[@pone.0237740.ref038]\] a link was found between sarcopenia and postoperative complications. To exclude the influence of other common factors in the sarcopenic population, univariate and multivariate analyses were used. The presence of complications was studied based on the Clavien--Dindo classification. Two articles \[[@pone.0237740.ref037],[@pone.0237740.ref038]\] considered a grade 2 or higher in the analyses. Three articles \[[@pone.0237740.ref031]--[@pone.0237740.ref033]\] separated their analysis considering a grade 2 or higher and a grade 3 or higher. Five articles \[[@pone.0237740.ref028]--[@pone.0237740.ref030],[@pone.0237740.ref034],[@pone.0237740.ref036]\] divided and specified in each of the grades 2, 3, 4 and 5. One of them \[[@pone.0237740.ref035]\] divided into all grades but did not specify the complications.

Another analysis of great interest refers to the division of complications into surgery and non-surgical \[[@pone.0237740.ref031]--[@pone.0237740.ref033],[@pone.0237740.ref037],[@pone.0237740.ref038]\]. Chen et al. (2018) \[[@pone.0237740.ref038]\] found significant differences in the two categories. Some authors \[[@pone.0237740.ref031]--[@pone.0237740.ref033],[@pone.0237740.ref037]\] found differences only in non-surgical complications.

In addition to the Clavien--Dindo classification, some articles used other parameters to perform the analysis: Kawamura et al. (2018) \[[@pone.0237740.ref037]\] investigated the occurrence of sepsis, and came to the conclusion that there is a relationship between this condition and sarcopenia.

It is worth mentioning that Huang et al. (2017) and Zhou et al. (2017) \[[@pone.0237740.ref032],[@pone.0237740.ref033]\] did not find a significant difference when considering grade 3 or higher. This suggests that the relationship would occur only when considering complications in general. Fukuda et al. (2016) \[[@pone.0237740.ref031]\] found only significant differences only in the most severe groups (grade 3 or higher) when analyzing complications in general.

One of the studies \[[@pone.0237740.ref028]\] also compared the exclusive use of decreased muscle mass as a risk factor and concluded that this is not a good indicator, and proper sarcopenia definition should be used to obtain consistent results.

Some articles also investigated the number of postoperative days in the hospital as an indirect assessment of complications \[[@pone.0237740.ref028],[@pone.0237740.ref029],[@pone.0237740.ref031]--[@pone.0237740.ref038]\]. Some of them \[[@pone.0237740.ref032],[@pone.0237740.ref033],[@pone.0237740.ref035],[@pone.0237740.ref036],[@pone.0237740.ref038]\] found a significant difference between the sarcopenic and control groups.

### 3.5.2 Sarcopenia and hospital readmission rate {#sec021}

From the analysis of the 30-day hospital readmission rate, all articles found a positive relation \[[@pone.0237740.ref028],[@pone.0237740.ref029],[@pone.0237740.ref032]--[@pone.0237740.ref034],[@pone.0237740.ref036],[@pone.0237740.ref038]\], however only one of them was statistically significant \[[@pone.0237740.ref034]\]. On the other hand, one article \[[@pone.0237740.ref035]\] analyzed the 90-day hospital readmission rate, and showed evidence that there is a significant difference in sarcopenics.

### 3.5.3 Sarcopenia and mortality {#sec022}

Unlike postoperative complications, sarcopenia does not appear to be associated with 30-day or 3-month mortality. Articles \[[@pone.0237740.ref028],[@pone.0237740.ref031]--[@pone.0237740.ref034],[@pone.0237740.ref037],[@pone.0237740.ref038]\] did not find differences in 30-day mortality.

However, when considering long-term mortality, sarcopenia can have an impact on patients' lives.

The survival study \[[@pone.0237740.ref030]\] identified sarcopenia as an independent risk factor for survival.

3.6 Meta-analysis {#sec023}
-----------------

### 3.6.1 Sarcopenia and complications {#sec024}

The meta-analysis corresponds to the assessment of sarcopenia as a risk factor for complications in patients undergoing digestive tract surgery.

After review, 11 publications were considered that reported the presence of sarcopenia and postoperative complications. The odds ratio (OR) values and their respective 95% confidence intervals (95% CI) were calculated.

In [Fig 3](#pone.0237740.g003){ref-type="fig"}, the forest plot is shown. Of the 11 publications, 10 of them found the presence of sarcopenia as a risk factor for post-surgical complications (p \<0.05). One study had no statistical evidence to reject the hypothesis that the OR value was different from 1 \[[@pone.0237740.ref031]\]. The global OR value was 3.0 (95% CI 2.53--3.55). The measure of heterogeneity I^2^ (Higgins heterogeneity measure) was 16%, a value considered as low heterogeneity. According to Cochran's Q heterogeneity test, the sample evidence did not allow us to reject the null hypothesis of non-heterogeneity (p = 0.29).

![Forest plot of the publications analysed in relation to sarcopenia and post-surgical complications.](pone.0237740.g003){#pone.0237740.g003}

The publication bias was assessed using the funnel plot ([Fig 4](#pone.0237740.g004){ref-type="fig"}). The graph represents each of the studies with the value of association and effect measures.

![Publication bias for studies that assessed sarcopenia as a factor associated with post-surgical complications.](pone.0237740.g004){#pone.0237740.g004}

The subgroup analysis for complications separated by type of surgery showed similar results. In gastrectomy studies \[[@pone.0237740.ref029]--[@pone.0237740.ref034],[@pone.0237740.ref036],[@pone.0237740.ref037]\] a total of 3649 patients were analysed. The global OR value was 3.09 (95% CI 2.44--3.92). Regarding the analysis of colorectal surgery studies \[[@pone.0237740.ref028],[@pone.0237740.ref038]\], a total of 518 patients were analysed. The global OR value was 2.71 (95% CI 1.45--5.07).

### 3.6.2 Sarcopenia and 30 days hospital readmission {#sec025}

The meta-analysis corresponds to the evaluation of sarcopenia as a risk factor for 30 days readmission in patients undergoing digestive tract surgery.

After reviews, 7 publications were considered that reported the presence of sarcopenia and 30 days readmission. The odds ratio (OR) values and their respective 95% confidence intervals (95% CI) were calculated.

In [Fig 5](#pone.0237740.g005){ref-type="fig"}, the forest plot is shown. Of the 7 publications, one found the presence of sarcopenia as a factor of 30 days readmission (p \<0.05)\[[@pone.0237740.ref034]\]. The global OR value was 2.2 (95% CI 1.44--3.36). The measure of heterogeneity I^2^ (Higgins heterogeneity measure) was 0%, a value considered as low heterogeneity. According to Cochran's Q heterogeneity test, the sample evidence did not allow us to reject the null hypothesis of non-heterogeneity (p = 0.790).

![Forest plot of the publications analysed regarding sarcopenia and hospital readmission (30 days).](pone.0237740.g005){#pone.0237740.g005}

The publication bias was assessed using the funnel plot ([Fig 6](#pone.0237740.g006){ref-type="fig"}). The graph represents each of the studies with the value of association and effect measures.

![Publication bias for studies that assessed sarcopenia as a factor associated with hospital readmission (30 days).](pone.0237740.g006){#pone.0237740.g006}

4. Discussion {#sec026}
=============

Sarcopenia is a pathological condition of increasing importance and increasingly prevalence, given the aging population and greater access to diagnostic methods. Patients at risk of developing this disease include the elderly, patients with chronic-degenerative diseases, and cancer patients. It is associated with an increased risk of adverse outcomes, including falls, fractures, postoperative complications, and mortality \[[@pone.0237740.ref040]\].

With technological advances and better procedural safety, more patients are eligible for gastrointestinal surgeries of various types, including resections of tumors and liver transplants, so that the study of factors that imply changes in the surgical risk of these patients is of great value for medical practice.

The prognostic influence of sarcopenia in surgical patients has received great attention in recent years, as attested by the profusion of articles and meta-analyses carried out investigating this relation\[[@pone.0237740.ref044]--[@pone.0237740.ref046]\]. Hajibandeh et al. (2019) analyzed the effect of sarcopenia on postoperative mortality in patients undergoing emergency abdominal surgeries, identifying longer hospital stays, greater need for an ICU, and increased mortality within 30 days (RR 2.15) and 1 year after surgery (RR 1.97)\[[@pone.0237740.ref045]\]. The presence of sarcopenia was also associated with increased length of hospital stay after pancreatic surgery in the meta-analysis by Ratnayake et al \[[@pone.0237740.ref046]\], although a higher risk of postoperative complications has not been identified, which was partially attributed to the heterogeneity of the data. Lanza et al. (2020) investigated patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma and found out that sarcopenia can be used as a predictor of survival, with an HR = 2.22 for reduced survival\[[@pone.0237740.ref044]\]. However, the majority of these studies used the term "sarcopenia" considered only reduction of muscle mass evaluated by tomography \[[@pone.0237740.ref045]--[@pone.0237740.ref047]\]. In specific populations, such as cirrhotic patients in a transplant waiting list, there are studies that have diagnosed sarcopenia by associating a measure of muscle strength with a measure of muscle mass---for example, handgrip strength assessed by dynamometer and image assessed by DEXA \[[@pone.0237740.ref048]\]. In the case of elective abdominal surgeries, virtually 100% of patients undergo abdominal CT scans before surgery; these images, combined with the simple measurement of muscle strength using a dynamometer, make it possible to carry out the preoperative diagnosis of sarcopenia. We believe that the association of imaging criteria with functional criteria increases the specificity of the diagnosis, making the prevalence data more robust and less dependent on cutoff points for muscle mass, in addition to enabling the allocation of preoperative resources to patients with greater potential of benefit. More recent studies have recognized the loss of muscle strength as a better predictive factor of adverse results than just a reduction in muscle mass \[[@pone.0237740.ref049],[@pone.0237740.ref050]\], and international guidelines recommend that the diagnosis of this condition be performed confirming loss of muscle strength coupled with the reduction of lean mass, using as a parameter of severity the presence or absence of reduced muscle performance \[[@pone.0237740.ref040]\].

Recent systematic reviews and meta-analysis that did not use the established international criteria for sarcopenia demonstrated no influence of sarcopenia \[[@pone.0237740.ref046],[@pone.0237740.ref051]\] or an odds ratio value for complications much lower than the one found in our analysis \[[@pone.0237740.ref052]--[@pone.0237740.ref054]\]. Comparing those results with ours clearly shows that, without proper diagnose of sarcopenia, its impact is underestimated. The use of radiological and clinical criteria, as suggested in our study, creates a more homogenous group, being a better predictor of the real impact of sarcopenia.

Therefore, in this review and meta-analysis, we seek to analyse the impact of sarcopenia in the postoperative period of gastrointestinal surgeries. To our knowledge, this is the first review that selected only articles that used functional and imaging criteria to define the diagnosis of sarcopenia, in accordance with international guidelines.

With these criteria, we found that the presence of sarcopenia is associated with an increased risk of postoperative complications (OR 3.01 \[95% CI 2.55--3.55\]) as well as an increase in hospital 30 days readmission (OR 2.2 \[95% CI 1.44--3.36\]), in patients undergoing gastrointestinal surgery. Increased complications in gastric cancer surgery and esophagectomy have also been identified. Studies have reduced heterogeneity, which increases confidence in the results. These findings confirm other studies that demonstrate sarcopenia as a factor with a worse prognosis, and may have important implications for the assessment of surgical risk and preoperative therapeutic management of these patients. For example, Yamamoto et al. (2017) \[[@pone.0237740.ref055]\] reported a physical exercise and nutritional optimization program in sarcopenic patients with gastric cancer implemented before surgery. Despite the reduced number of patients and the duration of the program, it was found that four patients reversed the condition of sarcopenia in the preoperative period.

Among the limitations of this analysis, we mention the presence of studies with oriental populations only, all of which were carried out in China or Japan. Thus, the results found may not be representative of the general population, and in particular, of the western population. In addition, all studies reported oncological surgeries, further limiting the analysed population.

The analysis of the impact of sarcopenia on mortality after surgery was not possible since the majority of studies in the period analysed were zero or extremely low, both in the group of sarcopenia and in the control group.

Another possible limitation of the present study is the selection of articles for systematic review and meta-analysis. Some articles did not make clear the method of assessing sarcopenia and, for this reason, did not enter the analysis. Moreover, another issue is the use of different cutoffs among studies, partially due to the absence of exact values to define sarcopenic patients homogenously.

Finally, considering that almost all patients undergoing elective gastrointestinal surgery will have a CT for surgical preoperative planning, adding strength measurement will have a low impact in cost and time, but significant impact on the proper diagnose of sarcopenia. This classification will give more accurate information about postoperative complications risk.

Therefore, in view of the reported data, we consider that the implementation of protocols that properly diagnose sarcopenia to be of great value in the preoperative evaluation of any patient who will undergo gastrointestinal surgery. In this sense, further studies that evaluate the impact of performing preoperative interventions (e.g. resistance exercise program, optimization of protein intake \[[@pone.0237740.ref056]\], vitamin D supplementation, among others) are necessary, potentially minimizing the incidence of adverse events and even postoperative mortality.

5. Conclusion {#sec027}
=============

Sarcopenia, when properly diagnosed, is associated with an increase in late postoperative complications, as well as an increase in the number of postoperative hospital readmissions for various types of gastrointestinal surgery. We believe that any preoperative evaluation should include, in a patient at risk, tests for the diagnosis of sarcopenia and appropriate procedures to reduce its impact on the patient's health. Future studies will help to determine the impact of such interventions on the rate of postoperative complications in these patients.

Supporting information {#sec028}
======================

###### 

(DOCX)

###### 

Click here for additional data file.

###### 

(DOC)

###### 

Click here for additional data file.

The authors are thankful to Justin Axel-Berg for the English corrections, Rossana V. Mendoza López for the statistical analysis, and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Processo n°2018/10430-6 and n° 2018/10423-0.

10.1371/journal.pone.0237740.r001

Decision Letter 0

Lanza

Ezio

Academic Editor

© 2020 Ezio Lanza

2020

Ezio Lanza

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

14 Jul 2020

PONE-D-20-18203

THE IMPACT OF SARCOPENIA ON POSTOPERATIVE OUTCOMES AFTER GASTROINTESTINAL SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS

PLOS ONE

Dear Dr. Meyer,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Find below some key points raised by the reviewers. Particularly, consider referring in your discussion to the following recent articles on Sarcopenia: 

- [https://doi.org/10.1371/journal.pone.0232371 ](https://doi.org/10.1371/journal.pone.0232371 )

\- <https://doi.org/10.1097/SLA.0000000000002679>

Please submit your revised manuscript by Aug 28 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Ezio Lanza, M.D.

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In the Methods section, please indicate whether a fixed- or random effects regression model was used for the data analysis conducted in your study.

3\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: [http://journals.plos.org/plosone/s/supporting-information](about:blank)

Reviewer\'s comments: 

Reviewer \#1: This is an interesting systematic review and meta-analysis on the impact of sarcopenia on the postoperative outcomes following gastrointestinal surgeries. The clinical question is well posed and the topic is timely an appropriate. Statistics are well performed. PRISMA guidelines are strictly respected and protocol registration on an international database makes the analysis of high quality. Conclusions are supported by the results. I have some comments that could improve the manuscript.

There is an important manuscript published in the literature a couple of years ago concerning Sarcopenia as a predictor of morbidity in gastrointestinal surgical oncology. This is a systematic review and meta-analysis (Simonsen et al. Ann. Surg. 2018). I don\'t know why this article is not even mentioned in your manuscript. Was this missed? You definetely have to comment this manuscript in your paper as it is a major one. Yours have some significant improvements i believe so please show the reader that it is worth it to have a new one on the topic.

You have correctly mentioned that because of the absolute prevalence of Eastern studies in your analysis, your results could not be reproducible among Westerners. I think that it is worth mentioning that another issue is the use of different cutoffs among studies as it is clear from your Tables. Indeed, some authors use recognized cutoffs to divide sarcopenic and non sarcopenic patients while others use ROC curves on their populations. Both methods have limitations of course and therefore this needs to be mentioned as a limitation in your study. We currently don\'t have an exact cutoff to define sarcopenic patients homogenously.

Finally, of course the real novelty here is that you consider the 1 and only correct definition of sarcopenia which is made up of both muscle mass and muscle strength . The authors should emphasize this in their study. In my opinion also in the title. If you leave your title as it is, you might get the reader confused. Indeed, when i read your title to review i thought that i was about t read something with no novelty (Very similar to the one from Simonsen et al.). But indeed you have something new and important to tell. Please consider giving your title some more appeal.

Reviewer \#2: This is a nice systematic review and meta-analysis to address the role of sarcopenia in the postoperative complications of gastrointestinal surgery. Authors have found that sarcopenia was significantly associated with an increase in late postoperative complications, as well as an increase in the number of postoperative hospital readmissions after gastrointestinal surgery. Thus, it is important to assess sarcopenia and provide appropriate interventions before surgery to reduce its impact on the patient\'s health. I think that this is a well-conducted systematic review according to the PRISM statement. However, liver transplantation should not be included in gastrointestinal surgery and the data should be removed from the analysis.

Minor point.

References 4 and 23 are overlapped.

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237740.r002

Author response to Decision Letter 0

29 Jul 2020

We really appreciate all the comments, we believe our text is now substantially better.

\#1: This is an interesting systematic review and meta-analysis on the impact of sarcopenia on the postoperative outcomes following gastrointestinal surgeries. The clinical question is well posed and the topic is timely an appropriate. Statistics are well performed. PRISMA guidelines are strictly respected and protocol registration on an international database makes the analysis of high quality. Conclusions are supported by the results. I have some comments that could improve the manuscript.

There is an important manuscript published in the literature a couple of years ago concerning Sarcopenia as a predictor of morbidity in gastrointestinal surgical oncology. This is a systematic review and meta-analysis (Simonsen et al. Ann. Surg. 2018). I don\'t know why this article is not even mentioned in your manuscript. Was this missed? You definetely have to comment this manuscript in your paper as it is a major one.
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Yours have some significant improvements i believe so please show the reader that it is worth it to have a new one on the topic.
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You have correctly mentioned that because of the absolute prevalence of Eastern studies in your analysis, your results could not be reproducible among Westerners. I think that it is worth mentioning that another issue is the use of different cutoffs among studies as it is clear from your Tables. Indeed, some authors use recognized cutoffs to divide sarcopenic and non sarcopenic patients while others use ROC curves on their populations. Both methods have limitations of course and therefore this needs to be mentioned as a limitation in your study. We currently don\'t have an exact cutoff to define sarcopenic patients homogenously.
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Finally, of course the real novelty here is that you consider the 1 and only correct definition of sarcopenia which is made up of both muscle mass and muscle strength . The authors should emphasize this in their study. In my opinion also in the title. If you leave your title as it is, you might get the reader confused. Indeed, when i read your title to review i thought that i was about t read something with no novelty (Very similar to the one from Simonsen et al.). But indeed you have something new and important to tell. Please consider giving your title some more appeal.
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Reviewer \#2: This is a nice systematic review and meta-analysis to address the role of sarcopenia in the postoperative complications of gastrointestinal surgery. Authors have found that sarcopenia was significantly associated with an increase in late postoperative complications, as well as an increase in the number of postoperative hospital readmissions after gastrointestinal surgery. Thus, it is important to assess sarcopenia and provide appropriate interventions before surgery to reduce its impact on the patient\'s health. I think that this is a well-conducted systematic review according to the PRISM statement. However, liver transplantation should not be included in gastrointestinal surgery and the data should be removed from the analysis.
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